Dr. Marcelo E. Lancman, MD

Dr. Lancman practices at Epilepsy & Neurophysiology Medical Consultants PA in Hackensack, New Jersey.

Dr. Lancman's NPI, 1609857010, was assigned on November 11, 2005. Dr. Lancman graduated from University of Buenos Aires in 1984. Dr. Lancman holds New Jersey license 67336.

Dr. Lancman's primary practice is Epilepsy & Neurophysiology Medical Consultants PA, at 20 Prospect Ave, Hackensack, NJ 07601 in Bergen County. The practice phone is (201) 996-3205.

Dr. Lancman's primary practice is Epilepsy & Neurophysiology Medical Consultants PA in Hackensack, New Jersey. Dr. Lancman is also affiliated with Hackensack University Medical Center. The medical group on file is Epilepsy & Neurophysiology Medical Consulting, PC. Dmand AI also links Dr. Lancman to 1 more hospital, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lancman practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Lancman's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Lancman's licenses on file in 3 states: New Jersey, Connecticut and New York.

CMS data shows 1,058 Medicare services from Dr. Lancman across 9 procedure codes in 2024, for 316 Medicare patients. Medicare paid $328,645 for them.

CMS counts 316 Medicare patients who saw Dr. Lancman in 2024. The largest group is under 65, with 152 patients. 70% of them have high cholesterol, and 60% have high blood pressure. 55% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lancman's median patient age at 41, with 53% women.

In 2024, Dr. Lancman wrote 2,379 Medicare Part D claims for 324 patients. 74% of them were for generic drugs. CMS names the drug for 2,232 of them, across 35 drugs with 11 or more claims each, at $857,693 in total drug cost. In 2023, CMS named 2,977 claims across 44 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lancman for performance year 2024, reported as part of a group. Dr. Lancman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lancman as offering telehealth.

Dmand AI links 21 papers to Dr. Lancman, published from 2012 to 2024. 2016 was the busiest year, with 4. The most frequent topics are Seizures, Epilepsy and Electroencephalography. Dr. Lancman has published most often in Epilepsy Behav. Dr. Lancman's most frequent co-authors are James W. Wheless, MD, Sami Mohamad Aboumatar, MD and Katherine McNaughton Moretz, MD.

Dmand AI links Dr. Lancman to 1 clinical trial. Conditions studied include Epilepsies, Partial and Epilepsy.

CMS Open Payments shows 69 general payments to Dr. Lancman from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Supernus Pharmaceuticals, Inc. paid the most, $324. It also lists 1 research payment totaling $160 in 2018.

Dr. Lancman graduated from University of Buenos Aires in 1984.